Science Explorer Back to mapMap
Discussion
Nonprofit · Plano · United States

AIM at Melanoma Foundation

aimatmelanoma.orgROR OpenAlex
Research works
1
◆ 0% vs 2018-21
Citations
68
106.2 per fractional work
Top-10% rate
23.1%
all institutions 10.0%
Open access
37%
world 40%
International
29%
world 18%
AIM at Melanoma Foundation

Not ranked overall: AIM at Melanoma Foundation is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does AIM at Melanoma Foundation work in?

In all years, 67% of research at AIM at Melanoma Foundation is in Health Sciences, 33% in Life Sciences. Its largest fields are Medicine (67%), Biochemistry, Genetics and Molecular Biology (33%).

Health Sciences: 0 fractional works · 66.7% of its workMedicine: 0 fractional works · 66.7% of its workLife Sciences: 0 fractional works · 33.3% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 33.3% of its workALL ITS WORKAIM at MelanomaFoundation1fractional works, all years
Life Sciences33%Health Sciences67%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 2 fields, with their numbers
    1. Medicine066.7%
    1. Biochemistry, Genetics and Molecular Biology033.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from AIM at Melanoma Foundation?

The most cited paper from AIM at Melanoma Foundation is "Guidelines of care for the management of primary cutaneous melanoma" (Susan M. Swetter, Hensin Tsao, Christopher Keram Bichakjian et al., 2018), with 735 citations. Next come "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134" (474) and "Systemic Therapy for Melanoma: ASCO Guideline" (270).

Most cited papers
#PaperReleasedCitations
1 Guidelines of care for the management of primary cutaneous melanoma Susan M. Swetter, Hensin Tsao, Christopher Keram Bichakjian et al. · Journal of the American Academy of Dermatology Nov 2018 735
2 Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 Michael B. Atkins et al. · Journal of Clinical Oncology Open access 27 Sep 2022 474
3 Systemic Therapy for Melanoma: ASCO Guideline Rahul Seth et al. · Journal of Clinical Oncology 31 Mar 2020 270
4 Systemic Therapy for Melanoma: ASCO Guideline Update Rahul Seth et al. · Journal of Clinical Oncology Open access 14 Aug 2023 224
5 Melanoma, Version 4.2014 Daniel G. Coit et al. · Journal of the National Comprehensive Cancer Network Open access May 2014 78
All 9 most cited papers, with filters and sorting

Which research topics does AIM at Melanoma Foundation publish most on?

By volume in 2022-now: Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research and Ocular Oncology and Treatments.

Melanoma and MAPK Pathways0Melanoma and MAPK Pathways: 0 fractional worksCancer Immunotherapy and…0Cancer Immunotherapy and Biomarkers: 0 fractional worksCAR-T cell therapy resea…0CAR-T cell therapy research: 0 fractional works
Molecular BiologyOncology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Melanoma and MAPK Pathways Molecular Biology 0 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 0 works
  3. 3 CAR-T cell therapy research Oncology 0 works
  4. 4 Ocular Oncology and Treatments Ophthalmology 0 works
  5. 5 Cutaneous Melanoma Detection and Management Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available37.0%not open63.0%

World: 40% of research is openly available.

with international co-authors28.6%domestic only71.4%

World: 18% is written across borders.

How has AIM at Melanoma Foundation's research output changed?

Output in 2022-2025 was 0% higher than in 2018-2021.

20152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Plano

All research institutions in Plano

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about AIM at Melanoma Foundation. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.